Linaclotide acetate for treating Chronic idiopathic constipation

Linaclotide acetate is currently in clinical development for the treatment of adults with chronic idiopathic constipation (CIC). Constipation is defecation that is problematic because of infrequent and/or hard stools, difficulty passing stools (often involving straining), or the sensation of incomplete emptying or anorectal blockage. Chronic is when the symptoms are present for at least three months. CIC is a health condition in which the person experiences long-time symptoms of constipation, but healthcare providers cannot identify a cause through standard tests. CIC disproportionately affects women, the elderly, and individuals of lower socioeconomic status. Other common risk factors of constipation include reduced caloric intake, sedentary lifestyle, decreased fibre intake, and usage of anti-inflammatory agents.